Combination of RAS inhibition and immunotherapy provides breakthrough for pancreatic cancer

This post was originally published on News-medical.net

You will shortly be re-directed to the publisher's website

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy by itself, according to researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine’s Abramson Cancer Center.